Analyst firms · Citigroup · KRYS

Citigroup KRYS price target and rating history

Krystal Biotech Inc. (KRYS) · Health Care

Citigroup rates Krystal Biotech Inc. (KRYS) Buy with a $309 price target, as of its latest action on Jan 6, 2026. It has published 3 rating actions on KRYS since October 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a KRYS price target in the last 12 months, the median target is $400. Citigroup's $309 is 23% below that.

Current rating
Buy
Price target
$309
Median target, all firms
$400
Actions on KRYS
3

Citigroup price target on KRYS

$309$235$160202420252026
Citigroup price target on KRYS, each point a stated target, October 2023 to January 2026.

Every Citigroup rating on KRYS

How other firms rate KRYS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Goldman SachsBuy$441Sep 24, 2026
RBC Capital MarketsOutperform$400Aug 14, 2026
Wolfe ResearchPeer PerformMar 27, 2026
CitigroupBuy$309Jan 6, 2026

Questions about Citigroup and KRYS

What is Citigroup's price target for KRYS?
Citigroup's latest stated price target for Krystal Biotech Inc. (KRYS) is $309, from its action on Jan 6, 2026.
What is Citigroup's rating on KRYS?
Citigroup rates KRYS Buy, a bullish rating, as of Jan 6, 2026.
When did Citigroup last change its view on KRYS?
On Jan 6, 2026, Citigroup upgrades to Buy from Neutral, price target $309.
How does Citigroup's KRYS target compare with other analysts?
Across 3 firms with a KRYS price target in the last 12 months, the median target is $400. Citigroup's $309 is 23% below that.

More KRYS rating histories

All Citigroup ratingsKRYS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.